Table I.
Ethnic-specific patterns of association of genetic variants at 8q24 with prostate cancer.
| Marker, region and position | African-Americansab (1614/837) | Japanese Americans (722/728) | Native Hawaiiansa(111/112) | Latinosa (637/633) | European Americansb (1182/942) | Phetc | Pooled OR (95% CI)d (unadjusted for other markers) | Pooled OR (95% CI)e (adjusted for other markers) |
| rs13254738, region 2 and 128173525 | 1.24 (1.09–1.42) 58% | 1.57 (1.33–1.83) 62% | 1.46 (1.00–2.12) 50% | 1.25 (1.07–1.46) 49% | 1.11 (0.97–1.26) 33% | 0.02 | 1.26 (1.18–1.36) | 1.18 (1.09–1.27) |
| rs6983561, region 2 and 128176062 | 1.34 (1.18–1.53) 40% | 1.78 (1.47–2.15) 16% | 3.17 (1.87–5.36) 12% | 1.99 (1.34–2.96) 3% | 1.16 (0.86–1.58) 4% | 0.001 | 1.51 (1.37–1.67) | 1.42 (1.28–1.58) |
| Broad11934905f, region 2 and 128200991 | 2.45 (1.65–3.62) 2% | — (—) <1% | — (—) 0% | — (—) <1% | — (—) 0% | — | 2.45 (1.65–3.62) | 2.24 (1.43–3.21) |
| rs6983267, region 3 and 128482487 | 1.43 (1.17–1.75) 84% | 1.22 (1.05–1.42) 32% | 1.29 (0.88–1.89) 28% | 1.05 (0.89–1.24) 62% | 1.13 (0.99–1.28) 51% | 0.17 | 1.18 (1.09–1.27) | 1.14 (1.03–1.26) |
| rs7000448g, region 3 and 128510352 | 1.33 (1.12–1.58) 61% | 1.23 (1.04–1.46) 24% | 1.38 (0.89–2.14) 22% | 1.29 (1.07–1.56) 29% | 1.14 (0.93–1.40) 37% | 0.83 | 1.26 (1.15–1.38) | 1.19 (1.08–1.32) |
| DG8S737–8g, region 1 and 128545681 | 1.25 (1.06–1.49) 16% | 1.48 (1.16–1.88) 16% | 2.55 (1.33–4.89) 15% | 1.46 (1.05–2.02) 6% | 1.45 (0.96–2.19) 5% | 0.27 | 1.39 (1.23–1.57) | 1.23 (1.08–1.40) |
| rs10090154, region 1 and 128601319 | 1.11 (0.94–1.32) 16% | 1.49 (1.23–1.81) 15% | 2.54 (1.61–4.02) 17% | 1.98 (1.49–2.61) 7% | 1.44 (1.17–1.76) 9% | 0.0005 | 1.43 (1.30–1.58) | 1.32 (1.17–1.50) |
Each cell of the table gives ORs (and 95% confidence intervals) for allele dosage effects along with the risk allele frequency in controls. ORs in this table do not correct for local ancestry estimates in African Africans, Latinos and Native Hawaiians, as we know local ancestry is correlated to some of these alleles.
Adjusted for genome-wide European ancestry.
OR adjusted for study.
P value testing for heterogeneity of allelic effects across all populations.
OR adjusted for population, study and genome wide European ancestry (African Africans, Latinos and Native Hawaiians).
OR adjusted for population, study and genome-wide European ancestry (African Africans, Latinos and Native Hawaiians) and all other markers in the same region (i.e. region 1, 2 or 3). Within a region, individuals missing data for any marker were excluded from analysis.
Analysis of Broad11934905 is presented for African-Americans only, as this is the only population in which the risk variant has an appreciable frequency.
A smaller number of subjects were genotyped for rs7000448 (2422 affected individuals and 2311 controls) and the microsatellite (3036 cases and 2208 controls).